Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | SORD | Q00796 | 1/20 | 0.31 |
| ▸ | GCG | P01275 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22185839 | 0.78 | CPB2 (0.44) | — | |
| SCHEMBL24495988 | 0.77 | CYP2E1 (0.41) | CYP2E1CYP2A6ARKCNH2 | |
| SCHEMBL22199093 | 0.77 | CYP2E1 (0.49) | RPS6KA5CYP17A1CYP2E1CYP2A6SORD | |
| SCHEMBL22185897 | 0.75 | CYP2E1 (0.36) | CYP17A1CYP2E1CYP2A6 | |
| SCHEMBL22184960 | 0.72 | PANK3 (0.37) | GCG | |
| SCHEMBL22185892 | 0.72 | TRPV1 (0.34) | CYP17A1CYP2E1CYP2A6HSP90AA1 | |
| SCHEMBL11901185 | 0.72 | GCG (0.36) | GCG | |
| SCHEMBL22185893 | 0.70 | SCD (0.36) | CYP2E1CYP2A6GCG | |
| SCHEMBL22184964 | 0.70 | CYP2A6 (0.66) | CYP2E1CYP2A6HSP90AA1AR | |
| SCHEMBL29448509 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200206233-A1 | HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS | IDH1, IDH2, IDH3A | RPS6KA5 2059/4885CYP17A1 438/4885CDC7 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.